Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Organisation › Details

Horama S.A.

Horama is a clinical-stage biotech company that develops gene-therapy treatments, based on recombinant adeno-associated virus (rAAV) vectors, targeting rare inherited retinal diseases. Horama was founded in 2014 by a complementary team of world-renown academic researchers who conducted, in 2011, one of the first clinical trials of gene therapy applied to ophthalmology in France, including: Philippe Moullier, Christian Hamel (1955-2017) and Vasiliki Kalatzis, from the French National Institute of Health and Medical Research (INSERM); and Michel Weber and Guyle`ne Le Meur, from the Nantes University Hospital in France. *

 

Period Start 2014-03-01 established
Products Industry gene therapy
  Industry 2 ophthalmology
Persons Person Placet, Christine (Horama 2016– Managing Director + Investor before Trophos CEO/CFO + France Biotech Board Member)
  Person 2 Greig, Russell G. (Greig Biotechnology Global Consulting before 30y at GSK most recently President of SR One)
     
Region Region Paris
  Country France
  Street 27 rue du Faubourg Saint-Jacques
  City 75014 Paris
    Address record changed: 2017-12-27
     
Basic data Employees n. a.
     
    * Document for �About Section�: Horama S.A.. (11/8/17). "Press Release: Horama Raises €19 million in a Series B Financing Round". Paris.
     
   
Record changed: 2018-09-18

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Horama S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81




» top